GO
Loading...

AstraZeneca PLC

More

  • Federal prosecutors in New York said David Post, 41, a product manager at the bank, received nonpublic information from a former Rutgers Business School classmate about three companies: Idenix Pharmaceuticals, Ardea BioSciences and ViroPharma Inc.. Prosecutors did not name the classmate, but on Oct. 14 they charged Zachary Zwerko, a former senior finance...

  • Federal prosecutors in New York said David Post, 41, a product manager at the bank, received nonpublic information from a former Rutgers Business School classmate about three companies: Idenix Pharmaceuticals, Ardea BioSciences and ViroPharma Inc.. Prosecutors did not name the classmate, but on Oct. 14 they charged Zachary Zwerko, a former senior finance...

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • Rapid UK economic growth slows slightly in 3rd quarter. LONDON- Britain's rapid economic recovery eased as expected during the third quarter, as services output growth slowed and manufacturing expanded at the weakest pace in 18 months, official data shows. BRUSSELS- France and Italy make fresh commitments to reform to persuade Germany and the European...

  • Oct 16- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said. There were no major safety issues associated with secukinumab, according to the review posted on the FDA website on Thursday- four days before a panel of outside advisers is...

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. drugmaker AbbVie has pulled the plug on its plan to buy Dublin- based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • *AbbVie board recommends shareholders vote against deal. *AbbVie to pay Shire $1.64 bln break fee if deal collapses. LONDON, Oct 16- U.S. pharmaceutical company AbbVie has pulled the plug on its plan to buy Dublin- based drugmaker Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.

  • Europe tanks on growth fears; CAC down over 3% Wednesday, 15 Oct 2014 | 11:37 AM ET

    European shares closed sharply on Wednesday as investors shunned risky assets on fears of crumbling global growth and weak economic data.

  • These companies are the greenest in the world Wednesday, 15 Oct 2014 | 6:13 AM ET

    Multinational giants BMW, Samsung and Unilever are among companies recognized for their green credentials, according to a new index.

  • AbbVie-Shire: Final nail in inversion coffin? Wednesday, 15 Oct 2014 | 5:34 AM ET

    Tax inversion may have dominated business news headlines for months – but that could all be about to change.

  • *AbbVie says reconsidering backing for deal. *AbbVie board to meet on Oct. 20. LONDON, Oct 15- Chicago- based AbbVie said it was reconsidering its $55 billion takeover of Shire weeks after the U.S. government moved to curb deals designed to reduce tax, wiping $13 billion off the London- listed firm's stock price.

  • LONDON, Oct 15- European shares fell on Wednesday, weighed down by UK healthcare stocks after U.S. suitor AbbVie Inc said it would reconsider its bid for UK pharmaceutical firm Shire. Shares in Shire fell nearly 30 percent in early deals after AbbVie said it intended to reconsider its recommendation to shareholders to vote in favor of the 32 billion pound merger...

  • Oct 14- AbbVie Inc said it intends to reconsider its recommendation to its shareholders to vote in favor of the 32 billion pound merger with Shire Plc due to the changing U.S. tax regulations. Chicago- based AbbVie, which makes top-selling arthritis drug Humira, is eager to buy Shire to reduce its U.S. tax bill by moving its tax base to Britain and to diversifying its...

  • New health care acquisition worth $12.2B Monday, 6 Oct 2014 | 8:53 AM ET

    The announcement is the latest in a recent spate of multibillion-dollar healthcare sector deals.

  • LONDON, Oct 6- AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. AstraZeneca said on Monday it was the first time the cardiology organizations had recommended one drug of this type over another in the treatment of acute...

  • Oct 5- Medical equipment supplier Becton Dickinson& Co has agreed to buy CareFusion Corp, a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcare sector deal. Becton said on Sunday it would pay a total of $58.00 a share- $49.00 in cash and 0.0777 of a share of Becton Dickinson- for...

  • Goldman tops M&A league, tax inversion deals soar Thursday, 2 Oct 2014 | 2:57 AM ET

    Goldman Sachs led the way in global deal-making in the first nine months of 2014, advising on 30.7 percent of all mergers and acquisitions.

  • Oct 1- An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday. The LDL reductions seen with the once-daily ETC-1002 pill were somewhat less than can be achieved by more powerful statins, such as Pfizer...

  • Oct 1- A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck& Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday.

  • Oct 1- Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared with a placebo in a mid-stage study involving 371 patients.